1. Scrip
  2. >>R&D
  3. >>Clinical Trials

BMS's Zeposia Shines in Ulcerative Colitis Phase III Study

Success Augurs Well For S1P Drug Class in UC

 
• By Sten Stovall

BMS’s S1P receptor modulator met endpoints in a Phase III trial treating patients with moderate to severe ulcerative colitis, boosting the drug class’s prospects in that condition.    

Colitis
Other S1P investigative drugs in UC include Arena’s etrasimod • Source: Shutterstock

Having just launched Zeposia (ozanimod) as a treatment for relapsing forms of multiple sclerosis, Bristol-Myers Squibb Co. is now well-positioned for using the sphingosine-1-phosphate (S1P) receptor modulator to treat ulcerative colitis (UC) after it met both primary endpoints and key secondary goals in a Phase III study.

BMS on 2 June said the Phase III True North study with Zeposia met its primary endpoint of clinical remission based on the three-component Mayo Score for induction at week...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

ASCO: Zepzelca Tecentriq Combo A Lung Cancer Success For Jazz and Roche

 
• By Andrew McConaghie

Small-cell lung cancer treatment is rapidly evolving, but Jazz and Roche are set to create a new maintenance therapy setting with their Zepzelca plus Tecentriq combination.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

ASCO: J&J Banks On T-Cell Engager’s Safety In Prostate Cancer

 
• By Andrew McConaghie

The company highlighted the KLK2-targeting agent’s safety at ASCO but it may have to rely on combinations to make pasritamig competitive.

More from R&D

ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player

 
• By Alaric DeArment

The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.

ASCO: Lupin Presents Early Data On PRMT5 Inhibitor

 
• By Vibha Ravi

ASCO sees the debut of Lupin’s PRMT5 inhibitor candidate LRNP7457, currently in Phase I studies in India. While no drug with this mechanism of action has been approved anywhere so far, several candidates are in clinical trials.

Vera’s Atacicept Sets A New Efficacy Bar With Phase III Results In IgAN

 
• By Mandy Jackson

Vera is the first company to report Phase III data for a dual inhibitor of APRIL and BAFF in IgA nephropathy. Atacicept provided a 42% placebo-adjusted reduction in proteinuria.